Gerresheimer stock extends pressure as 2025 numbers and guidance matter

Gerresheimer stock reflects the latest verified company data, with the German packaging and medical technology group reporting fiscal 2025 revenue of EUR 2.03 billion and adjusted EBITDA of EUR 398.2 million, while the adjusted EBITDA margin stood at 19.6%. The company's ISIN is DE000A0LD6E6, and the most recent investor relations material remains the reference point for the shares.

EUR 2.03 billion revenue

In fiscal 2025, Gerresheimer reported revenue of EUR 2.03 billion, compared with EUR 1.99 billion in the prior year, which shows a year-over-year increase of about 2%. Adjusted EBITDA reached EUR 398.2 million in fiscal 2025, up from EUR 388.4 million a year earlier, while the margin moved to 19.6% from 19.5%.

For investors, that combination matters more than a single day move because it ties valuation to operating execution. The numbers point to a business that kept profitability stable while adding modest top-line growth.

Margin at 19.6%

Gerresheimer's 19.6% adjusted EBITDA margin in fiscal 2025 gives a clean profitability marker for the current stock story. The absolute EBITDA gain of EUR 9.8 million year over year was small, but it still moved in the right direction alongside higher sales.

The company also said it expects to continue focusing on its core markets in medical devices and pharma packaging, where contract visibility and product mix are central to margin development. That operating mix is what keeps the stock linked to report season rather than short-term commentary alone.

Medical packaging focus

Gerresheimer remains centered on pharma and healthcare packaging, including glass and plastic packaging systems, drug delivery devices, and containment solutions. That product mix matters because it helps explain why revenue, EBITDA, and margin are the figures investors tend to track first.

The company reported adjusted EBITDA of EUR 398.2 million in fiscal 2025, so even a modest change in the sales line can have a noticeable effect on operating leverage. A business built around regulated end markets often lives or dies on that leverage.

Latest stock reference

Without a fresh market quote in the available evidence, the fiscal 2025 report provides the cleanest current anchor for Gerresheimer stock. The latest verified figures remain revenue of EUR 2.03 billion, adjusted EBITDA of EUR 398.2 million, and an adjusted EBITDA margin of 19.6% in fiscal 2025.

Packaging and devices

Gerresheimer's portfolio includes primary packaging for pharmaceuticals and delivery systems that serve drug manufacturers and healthcare customers. Those businesses are the main reason the stock is usually read through operating metrics rather than broad consumer demand.

Financial backdrop

The year-over-year gain in revenue from EUR 1.99 billion to EUR 2.03 billion was modest, but the stable margin suggests the group protected profitability while growing sales. That is the key financial backdrop for the shares until the next official update.